3.2. Primary Endpoint Measurement
After 24 weeks of treatment, 8 (13%) of the 60 patients in the test group had substantial improvement in degree of liver fat content, and the degree of liver fat content decreased from moderate and severe grade to mild grade. In contrast, 4 of 60 patients (6%) in the metformin group saw their liver fat content drop from moderate or severe to mild. Statistical analysis showed that the differences in the test group before and after treatment and compared with the metformin group were statistically significant. The number of patients with moderate or lower liver fat content in the pioglitazone-metformin combined treatment group increased from 46 (76.7%) to 54 (90.0%) and the metformin group increased from 43 (71.7%) to 47 (78.3%). The changes before and after treatment in the pioglitazone-metformin combined treatment group were statistically significant (Compared with the metformin group, pioglitazone-metformin combined treatment was associated with a significant decrease in 